 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 July 1993 | Volume 119 Issue 2 | Pages 110-115
Objective: To determine the long-term course of non-A, non-B post-transfusion hepatitis.
Design: Follow-up in 1989 to 1992 of patients prospectively identified as having contracted non-A, non-B post-transfusion hepatitis between 1972 and 1980.
Setting: A university hospital.
Patients: Patients who were prospectively followed from receipt of blood products and in whom otherwise unexplained abnormalities in their serum alanine aminotransferase levels developed without serologic evidence of exposure to hepatitis A or B.
Measurements: The presence or absence of clinical evidence of liver failure or symptoms of chronic hepatitis.
Results: Of 90 patients identified in the 1970s, 80 were recontacted and evaluated between 1989 and 1992. Based on the current status of these 80 patients and on the last known status of the remaining patients, the following observations were made: 1) Although about 40% had some symptoms during the early phase of the disease, none subsequently experienced significant clinical problems related to hepatic inflammation; 2) eight patients [seven with chronic hepatitis] developed hepatic failure; and 3) life-table analysis showed that the probabilities of developing clinical evidence of cirrhosis after 16 years of disease in the entire cohort, in the subgroup who developed chronic hepatitis, in the patients who had hepatitis C, and in those with chronic hepatitis C were 18%, 21%, 17%, and 20%, respectively.
Conclusions: For most of the study patients, non-A, non-B post-transfusion hepatitis was a biochemical and histologic disease that had not yet caused hepatic symptoms. If hepatic failure does occur, it is usually seen only after 10 or more years of disease. Before that time, many infected persons die due to other disease processes.
Author and Article Information
From the Center for Health Sciences, University of California, Los Angeles, California.
ARTICLE
Non-A, Non-B Post-Transfusion Hepatitis: Looking Back in the Second Decade
Requests for Reprints: Ronald L. Koretz, MD, Department of Medicine, Olive View Medical Center, 14445 Olive View Drive, Sylmar, CA 91342.
Acknowledgments: The authors thank Sally Memmott and Sylvia Anguiano for assistance in revising the manuscript and Deborah Lott for editorial assistance.
This article has been cited by other articles:
|
|
 |
|
  A. M. Guiltinan, Z. Kaidarova, B. Custer, J. Orland, A. Strollo, S. Cyrus, M. P. Busch, and E. L. Murphy Increased All-Cause, Liver, and Cardiac Mortality among Hepatitis C Virus-seropositive Blood Donors Am. J. Epidemiol., March 15, 2008; 167(6): 743 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Wong and S. S. Lee Hepatitis C: a review for primary care physicians Can. Med. Assoc. J., February 28, 2006; 174(5): 649 - 659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Krahn, J. B. Wong, J. Heathcote, L. Scully, and L. Seeff Estimating the Prognosis of Hepatitis C Patients Infected by Transfusion in Canada between 1986 and 1990 Med Decis Making, January 1, 2004; 24(1): 20 - 29. [Abstract] [PDF]
|
|
|
|
 |
|
 J. A. Salomon, M. C. Weinstein, J. K. Hammitt, and S. J. Goldie Cost-effectiveness of Treatment for Chronic Hepatitis C Infection in an Evolving Patient Population JAMA, July 9, 2003; 290(2): 228 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Castera, C Hezode, F Roudot-Thoraval, A Bastie, E-S Zafrani, J-M Pawlotsky, and D Dhumeaux Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies Gut, February 1, 2003; 52(2): 288 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Salomon, M. C. Weinstein, J. K. Hammitt, and S. J. Goldie Empirically Calibrated Model of Hepatitis C Virus Infection in the United States Am. J. Epidemiol., October 15, 2002; 156(8): 761 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Goedert, M. E. Eyster, M. M. Lederman, T. Mandalaki, P. de Moerloose, G. C. White II, A. L. Angiolillo, N. L. C. Luban, K. E. Sherman, M. Manco-Johnson, et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections Blood, August 13, 2002; 100(5): 1584 - 1589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Franchini, G. Rossetti, A. Tagliaferri, F. Capra, E. de Maria, C. Pattacini, G. Lippi, G. Lo Cascio, M. de Gironcoli, and G. Gandini The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders Blood, September 15, 2001; 98(6): 1836 - 1841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Simmonds 2000 Fleming Lecture. The origin and evolution of hepatitis viruses in humans J. Gen. Virol., April 1, 2001; 82(4): 693 - 712. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. R Osella, G. Misciagna, V. M Guerra, M. Chiloiro, R. Cuppone, A. Cavallini, and A. Di Leo Hepatitis C virus (HCV) infection and liver-related mortality: a population-based cohort study in southern Italy Int. J. Epidemiol., October 1, 2000; 29(5): 922 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Thomas, J. Astemborski, R. M. Rai, F. A. Anania, M. Schaeffer, N. Galai, K. Nolt, K. E. Nelson, S. A. Strathdee, L. Johnson, et al. The Natural History of Hepatitis C Virus Infection: Host, Viral, and Environmental Factors JAMA, July 26, 2000; 284(4): 450 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Degos, C Christidis, N Ganne-Carrie, J-P Farmachidi, C Degott, C Guettier, J-C Trinchet, M Beaugrand, and S Chevret Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death Gut, July 1, 2000; 47(1): 131 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Liang, B. Rehermann, L. B. Seeff, and J. H. Hoofnagle Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C Ann Intern Med, February 15, 2000; 132(4): 296 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Seeff, R. N. Miller, C. S. Rabkin, Z. Buskell-Bales, K. D. Straley-Eason, B. L. Smoak, L. D. Johnson, S. R. Lee, and E. L. Kaplan 45-Year Follow-up of Hepatitis C Virus Infection in Healthy Young Adults Ann Intern Med, January 18, 2000; 132(2): 105 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Jonas Hepatitis C Infection in Children N. Engl. J. Med., September 16, 1999; 341(12): 911 - 913. [Full Text]
|
|
|
|
|
|
S. I. Strasser, K. M. Sullivan, D. Myerson, C. L. Spurgeon, B. Storer, H. G. Schoch, C. S. Murakami, and G. B. McDonald Cirrhosis of the Liver in Long-Term Marrow Transplant Survivors Blood, May 15, 1999; 93(10): 3259 - 3266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Davis, R. Esteban-Mur, V. Rustgi, J. Hoefs, S. C. Gordon, C. Trepo, M. L. Shiffman, S. Zeuzem, A. Craxi, M.-H. Ling, et al. Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C N. Engl. J. Med., November 19, 1998; 339(21): 1493 - 1499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Locasciulli, M. Testa, P. Pontisso, L. Benvegnu, D. Fraschini, A. Corbetta, F. Noventa, G. Masera, and A. Alberti Prevalence and Natural History of Hepatitis C Infection in Patients Cured of Childhood Leukemia Blood, December 1, 1997; 90(11): 4628 - 4633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Cesaro, M. G. Petris, F. Rossetti, R. Cusinato, C. Pipan, M. Guido, L. Masiero, G. A. Botta, G. A. Meloni, and L. Zanesco Chronic Hepatitis C Virus Infection After Treatment for Pediatric Malignancy Blood, August 1, 1997; 90(3): 1315 - 1320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Tong, N. S. El-Farra, A. R. Reikes, and R. L. Co Clinical Outcomes after Transfusion-Associated Hepatitis C N. Engl. J. Med., June 1, 1995; 332(22): 1463 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 LONG-TERM OUTCOME OF POST-TRANSFUSION NON-A, NON-B HEPATITIS Journal Watch (General), August 3, 1993; 1993(803): 4 - 4. [Full Text]
|
|
Article
